Clinical management of human immunodeficiency virus type 1 (HIV-1) infection and implementation of treatment strategies rely on the quantitative measurement of HIV-1 RNA in plasma (26, 35) . A variety of quantitative viral load assays have been developed; they differ in sensitivity, dynamic range, target region, sample volume, specimen preparation, methods of nucleic acid amplification, and detection (20a, 21, 22, 28) . Most of these tests were calibrated against a well-characterized standard stock of subtype B HIV-1 RNA prepared by the Viral Quality Assurance Laboratory of the AIDS Clinical Trials Group (43) . Although the majority of viral load monitoring is currently performed in North America and Europe, where HIV-1 group M subtype B infections predominate, subtype B represents only about 3% of HIV-1 infections worldwide. With the continued evolution of the HIV-1 epidemic, increasing numbers of non-subtype-B infections are being identified in Europe and the United States (1, 3, 7, 17) . In France, a study of blood donors from 1985 to 1995 revealed an increase in the prevalence of non-subtype-B infections from 4% to more than 20% over the 10-year period (4) . Moreover, as a result of coinfection of individuals with viral strains of more than one subtype, increasing numbers of intersubtype recombinant forms of HIV-1 are being observed (31, 34) . Intergroup (group M-group O) recombinant viral strains have also been identified (30, 40) . In fact, of the completely sequenced HIV-1 genomes, nearly 20% have a mosaic structure consisting of at least two subtypes (33) .
Given the continued global expansion of non-subtype-B and recombinant forms of HIV-1, it is important that commercial nucleic acid-based tests detect and quantify accurately even the most genetically divergent HIV-1 strains. The impact of genetic variation on quantification by viral load assays has been well documented and may include underquantification or even complete lack of detection (2, 8, 10, 18, 19, 24, 29) . Recombination between distantly related strains may further contribute to the emergence of HIV-1 variants that are not detected efficiently by current molecular tests.
Comparison of viral load assays has been complicated by the lack of universal standards and/or quality control panels that encompass non-B subtypes. A panel of 30 HIV-1 isolates representing group M subtypes A to G was recently developed and characterized at the Walter Reed Army Institute of Research (WRAIR, Bethesda, Md.) (20, 27) . Ultimately, calibrated standards prepared from these or similar isolates will be used to evaluate the performance of viral load assays.
In the present study, we evaluated the performance of three commercial HIV-1 ultrasensitive viral load assays, LCx HIV RNA Quantitative assay (LCx HIV; Abbott Laboratories, Abbott Park, Ill.), AMPLICOR HIV-1 MONITOR version 1.5 ultrasensitive test (MONITOR v1.5; Roche Diagnostics, Branchburg, N.J.), and Quantiplex HIV-1 RNA version 3.0 assay (bDNA v3.0; Bayer Diagnostics, Emeryville, Calif.), with dilution series of 39 virus isolates. The viruses represent HIV-1 group M subtype A to G and group O strains and include the WRAIR clade panel. In addition, gag-encoded p24 (gag p24),
RESULTS

Genetic analysis of viral isolates.
Thirty-nine HIV-1 isolates were used to evaluate the three commercial viral load assays. The country of origin and group and subtype assignments for each isolate are shown in Table 1 . Subtypes for the WRAIR isolates (27) were based on limited sequence analysis of regions of the gag and/or env genes obtained from proviral DNA. The complete genome sequence was available for only four of the samples: CRF-AG (IbNG), DJ263; C, ETH2220; CRF-AE, CM240; and G, HH8793. To increase the integrity of group and subtype assignments three distinct regions (gag p24/pol IN/env gp41 IDR) of the genome were sequenced from each isolate. Based on the phylogenetic analysis (data not shown), the panel was composed of the following group M subtypes: three A, seven B, six C, four D, eight CRF-AE, four F, one G, and four intersubtype recombinants (two CRF-AG [IbNG], one A/G/G, and one B/A/B); it also contained two group O viruses. Of note, the additional sequence information obtained for isolate CM237, previously reported as subtype B, revealed that it is an intersubtype A-B recombinant with pol IN derived from subtype A.
Viral load determination. To assess the linearity of quantification across the dynamic ranges of the viral load assays, seven dilutions each of the 39 viral isolates were prepared with HIV-1-seronegative human plasma. Concentrations of the serial fivefold dilutions were expected to target from the ULQ to below the LLQ (50 RNA copies/ml) of all three assays. All 273 dilution panel members were evaluated in each of three commercial assays: LCx HIV assay, MONITOR v1.5 test, and bDNA v3.0 assay. The linear regression of each isolate dilution series was calculated from panel members quantified within the assay dynamic ranges. Results for representative HIV-1 group M subtypes A through G and group O are shown in Fig.  1a and b. For all 37 group M isolates, a linear decrease in quantification was observed across each dilution series in all three assays. No subtype-specific deficiency was apparent for any of the assays. Correlation coefficients for the LCx HIV assay, MONITOR v1.5 test, and bDNA v3.0 assay ranged from 0.9786 to 0.999, 0.9765 to 0.9985, and 0.9736 to 0.999, respectively. In contrast, group-specific differences between the assays were readily apparent. Relative to the LCx HIV assay, bDNA v3.0 detected but consistently underquantified both group O isolates by 0.7 to 1.21 log 10 copies/ml across the assay dynamic range. MONITOR v1.5 failed to detect any of the group O panel members. In a comparison of the LCx HIV assay and the MONITOR v1.5 test, 209 of 273 samples (76.6%) were quantified by both assays. Of the 209, 20 had viral loads above the ULQ of the MONITOR v1.5 test. The 189 dilutions with viral loads falling within the dynamic ranges of both assays are plotted in Fig. 2 . All group M isolates were quantified efficiently by both assays. The observed correlation was 0.9494, with a slope of 0.9587. Viral loads determined for all 189 dilutions were within one log 10 copy/ml between the assays; in fact, 175 of 189 viral loads (92.6%) were within 0.5 log 10 . Ten individual dilutions, including 4 A, 1 C, 1 CRF-AE, and 4 CRF-AG (IbNG), were quantified at 0.51 to 0.85 log 10 copies/ml higher in the MONITOR v1.5 test than in the LCx HIV assay. Relative to the LCx HIV assay, the MONITOR v1.5 test underquantified four individual dilutions (three subtype CRF-AE and one subtype B) by 0.52 to 0.75 log 10 copies/ml. The most notable difference between the assays was the inability of the MONITOR v1.5 test to detect either of the group O dilution series.
When the LCx HIV assay was compared to the bDNA v3.0 assay, 207 of 273 samples (75.8%) were quantified by both assays. Six samples were above the ULQ of the bDNA v3.0 assay. Figure 3 depicts a scatter diagram of the 201 dilutions with viral loads within the dynamic ranges of both assays. The observed correlation was 0.9498, with a slope of 0.8348. With two exceptions, viral loads were within one log 10 copies/ml between the assays; moreover, for 172 of 201 dilutions (85.6%), results were within 0.5 log 10 . For 13 individual dilutions, including 3 A, 5 C, 4 CRF-AG (IbNG), and 1 A/G/G, viral loads were 0.52 to 0.85 log 10 copies/ml higher in the bDNA v3.0 assay than in the LCx HIV assay. The bDNA v3.0 assay underquantified 14 individual dilutions (1 C, 1 D, 4 CRF-AE, 2 F, 1 mosaic, and 5 group O) by 0.51 to 1.0 log 10 copies/ml relative to the LCx HIV assay. Although the bDNA v3.0 assay detected group O samples, the values were consistently underestimated compared to those from the LCx HIV assay. In fact, two group O panel members were underquantified by 1.21 log 10 RNA copies/ml relative to the results from the LCx HIV assay.
Of the 201 of 273 samples (73.6%) quantified by both the MONITOR v1.5 test and the bDNA v3.0 assay, 21 had viral loads above the ULQ of one or both assays. Figure 4 shows a scatter diagram of the 180 dilutions with viral loads within the dynamic ranges of both tests. The correlation was 0.9663, with a slope of 1.1088. Viral loads for all dilutions were within 1 log 10 copies/ml between the assays, and 90.6% of them were within 0.5 log 10 . Relative to MONITOR v1.5, bDNA v3.0 underquantified 13 individual dilutions (2 A, 1 C, 2 D, 1 CRF-AE, and 7 F) by 0.52 to 0.77 log 10 copies/ml. Viral loads determined by the bDNA v3.0 assay were 0.55 to 0.84 log 10 copies/ml higher for four individual dilutions (one C, two CRF-AE, and one G) than were those determined by the MONI-TOR v1.5 test.
Nucleotide mismatches at primer and probe sites. Genetic characterization of the viral isolates included sequence analysis of pol IN and gag p24, target regions of the LCx HIV assay and the MONITOR v1.5 test, respectively. This characterization provided the opportunity to examine nucleotide conservation within primer and probe binding sites for these assays. Fewer mismatches were observed for the LCx HIV assay than for the MONITOR v1.5 test (Table 2 ). For group M isolates, the LCx HIV assay had a mean number of total nucleotide mismatches of 1.0 (range, 0 to 3 mismatches). In contrast, the MONITOR v1.5 test had three times more total nucleotide mismatches, with a mean of 3.2 changes (range, 0 to 8). At the forward primer, reverse primer, and probe sites, the mean numbers of nucleotide mismatches for group M samples were 0.6, 0.3, and 0.1, respectively, in the LCx HIV assay and 1.2, 0.6, and 1.3 in the MONITOR v1.5 test. For the two group O samples, the LCx HIV assay had a total of 5 mismatches, in contrast to a mean of 22 (range, 21 to 23) changes observed with the MON-ITOR v1.5 test. In the LCx HIV assay, the largest number of mismatches was observed for the forward primer and group O sequences (mean and range, four). For the 39 pol IN sequences examined, 92.3% of samples had two or fewer total nucleotide mismatches at the primer and probe binding sites in the LCx HIV assay. In contrast, only 38.5% of the gag p24 sequences had two or fewer mismatches at the MONITOR v1.5 test primer and probe binding sites.
DISCUSSION
First-generation HIV-1 quantitative tests were developed and standardized by use of sequence information derived primarily from subtype B infections. Because nucleic acid-based assays depend on hybridization, primer and probe mismatches with non-subtype-B isolates can significantly reduce the efficiency of quantification, thus severely limiting the utility of these tests. Within the last few years, viral load assays with improved performance characteristics for non-subtype-B HIV-1 variants have become available. The ultrasensitive MONITOR v1.5 test has incorporated a new primer set, modifications in VOL. 39, 2001 COMPARATIVE PERFORMANCE OF THREE VIRAL LOAD ASSAYScycling conditions, and increased sample volume, resulting in significant improvement in subtype detection and assay sensitivity (13, 42) . The ultrasensitive LCx HIV assay utilizes RT-PCR and targets a highly conserved region of pol IN to provide subtype-independent quantification (20a, 39). The addition of a new target probe set, optimization of the buffer to increase signal, and incorporation of isoC and isoG into the probe binding regions have resulted in enhanced bDNA v3.0 assay specificity and sensitivity (25 (20, 27) . A current limitation of this panel is that in most cases, the subtype was designated based on limited sequence information. Assignment of a subtype based on analysis of an individual region of the genome can be unreliable, particularly for isolates derived from regions where multiple subtypes cocirculate (34) . Thus, when target regions differ between assays, such a subtype designation may not be predictive of the ability of each test to quantify HIV-1 accurately. In fact, based on additional data for the gag p24 and pol IN regions generated in this study, isolate CM237, previously designated as subtype B based on env, was shown to be a B/A/B (gag, pol, env) recombinant virus. Complete genome characterization would increase the value of the panel and would allow examination of nucleotide mismatches regardless of assay target region.
Of interest, although the viral loads determined by the three assays were in close agreement, they were 0.5 to 1.5 log 10 copies/ml lower than the theoretical virion counts predicted by either EM or p24 antigen measurements. This finding highlights a critical issue in the construction of quality control panels, namely, the method(s) used to calibrate virus stocks. For the WRAIR panel, determination of p24 antigen concentration and virus particle count by EM were previously shown to be highly correlated (27) . Based on our data, use of multiple quantitative assays to establish a nominal value would be the most reliable method of calibrating virus stocks to be used for nucleic acid testing.
In the present study, dilution series of 39 virus isolates were quantified using three commercial ultrasensitive viral load assays: LCx HIV assay, MONITOR v1.5 test, and bDNA v3.0 assay. For group M isolates (subtypes A to G), there was a high degree of correlation between quantified values obtained across the dynamic ranges for all three tests, and no subtypespecific differences were observed. These data are consistent with the results obtained with HIV-1-infected plasma, showing broad subtype specificity of the LCx HIV assay and improved subtype detection by MONITOR v1.5 relative to earlier-generation tests, particularly for subtypes A, E, F, and G (2, 39, 42). As observed previously, there was close agreement between the MONITOR v1.5 test and the bDNA v3.0 assay for subtype B specimens (12, 16) . Our data extend the observation to other group M subtypes (A to G) and to circulating intersubtype recombinant forms of the virus. These results contrast with results obtained with earlier versions of these assays (10, 18) .
When dilution profiles of each isolate were examined, all quantified isolates had linear correlation coefficients of better than 0.97 for all three assays. For group M isolates, values quantified across the assay dynamic ranges were within 1 log difference among the three commercial tests. Although there was a tendency of MONITOR v1.5 to underquantify high-end panel members relative to the other tests, the molecular basis for this reduction is unclear. At the low end of the titration series (near 50 copies/ml LLQ), 8 to 12% of the group M dilution panel members were quantified by a single assay. Since quantitative assays are less precise around the LLQ and values fluctuate statistically, single-replicate testing of samples with low viral titers may not predict accurately the virus concentrations in these dilution panel members.
Although HIV-1 group O strains are endemic to West Central Africa and represent a small proportion of total HIV infections, they have attained a relatively widespread distribution, having been identified in France, Spain, Germany, Belgium, and the United States (15, 32, 36, 37) . Moreover, the recent identification of intergroup (M-O) recombinant strains (30, 40) raises the possibility that genetically divergent subgenomic regions of group O viruses may become even more widespread when placed in the context of group M genomes. This type of recombination has the potential to dramatically increase the effective global distribution of HIV-1 group O. Thus, it has become increasingly important that viral load assays accurately quantify even the most genetically divergent HIV-1 variants.
Of the three assays examined, only the LCx HIV assay demonstrated the ability to detect and reliably quantify group O viruses. The linear quantification of the two group O strains by the LCx HIV assay is consistent with its performance with group O virus-infected plasma samples (39) . The performance of the bDNA v3.0 assay with serial dilutions of group O isolates was considerably less robust. Relative to the LCx HIV assay, values ranged from 0.7 to 1.2 log 10 copies/ml lower with the bDNA v3.0 assay, and several of the low-end dilutions were not detected. Thus, although the bDNA v3.0 assay is capable of detecting high-titer group O viruses, the accuracy of quantification is suspect, limiting its utility for monitoring group O virus-infected patients (23) . The MONITOR v1.5 test failed to detect any of the group O dilutions analyzed. This result is particularly striking when one considers that both the LCx HIV and the bDNA v3.0 assays measured Ͼ4 log copies of virus/ml at the lowest dilution of group O isolate 3012, yet the MON-ITOR v1.5 test failed to detect this dilution panel member. Sequence characterization of the viral isolates included the target regions of the MONITOR v1.5 test (gag p24) and the LCx HIV assay (pol IN). For the group M isolates examined, a higher degree of nucleotide conservation was observed for the LCx HIV assay primer and probe sites. A maximum of three total mismatches were observed in the LCx HIV pol IN target region, compared to eight total mismatches in the MONITOR v1.5 gag p24 target region. The isolates had two or fewer mismatches in 100, 97, and 100% of cases for the forward primer, reverse primer, and probe in the LCx HIV assay and 62, 100, and 92% of cases in the MONITOR v1.5 test, respectively. The maximum number of mismatches in the MONI-TOR v1.5 test was observed with subtypes A, F, G, and CRF-AE. A similar analysis of 290 genetically diverse HIV-1- VOL. 39, 2001 COMPARATIVE PERFORMANCE OF THREE VIRAL LOAD ASSAYS 867 infected plasma samples revealed up to five total nucleotide mismatches in the primer and probe binding sites in the LCx HIV assay, whereas up to 12 were identified in the MONITOR v1.5 test (39) . The CRF-AG (IbNG) isolate, DJ263, trended slightly lower in the LCx HIV assay than in either the MON-ITOR v1.5 test or the bDNA v3.0 assay, particularly at the high end of the dynamic range, but there was no apparent molecular basis for the difference in quantification. The subtype A isolate, UG273, also trended slightly lower in the LCx HIV assay. For this isolate, three nucleotide mismatches were identified within the reverse primer binding site, although none was present at the critical 3Ј end of the primer. Analysis of the primer and probe target regions in the genetically divergent group O isolates revealed a significant difference between the assays. Whereas the LCx HIV assay had up to 5 total mismatches at primer and probe binding sites, the MONITOR v1.5 test had 21 to 23 mismatches. The large number of nucleotide mismatches provides a molecular basis for the observed inability of MONITOR v1.5 to detect group O samples. Based on the quantification of 37 dilution series of genetically diverse group M isolates, the LCx HIV assay, MONITOR v1.5 test, and bDNA v3.0 assay perform equivalently for group M strains. All group M subtypes (A to G) showed linear dilution profiles across the assay dynamic ranges. In contrast to group M isolates, group O isolates were efficiently quantified (8) 22 (21) (22) (23) by only the LCx HIV assay. The bDNA v3.0 assay detected but consistently underquantified group O isolates, and the MON-ITOR v1.5 test failed to detect them. Based on these data, the LCx HIV assay provides a desirable alternative to existing commercial assays for monitoring viral loads. The high level of nucleotide conservation within the target region allows quantification of even the most genetically diverse HIV-1 isolates, those of group O. In an era of increasing numbers of infections with recombinant forms of HIV-1 and an ever-changing global distribution of subtypes, the subtype-and group-independent performance of the LCx HIV assay makes it a valuable method for monitoring of patients.
